Here are the DEF 14A proxy statements from Biogen Inc. (BIIB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BIIB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIIB filings page.
Biogen Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 9, 2026. Proposals include electing 10 directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, and an advisory vote on executive pay.
The proxy highlights a late-stage pipeline and notes a 2026 merger agreement with Apellis Pharmaceuticals, expected to add EMPAVELI and SYFOVRE and expand into nephrology and retinal diseases. Biogen outlines extensive board refreshment, with most independent directors appointed since 2019 and an independent chair structure transitioning to Dr. Maria C. Freire.
Executive compensation changes respond to 67.7% Say on Pay support in 2025, adding caps when revenue and EPS underperform, introducing a pipeline metric to performance stock units, raising the rTSR target to the 55th percentile, and tightening CEO bonus alignment to company results. The proxy also details corporate responsibility efforts, including more than $34.6 million in 2025 community contributions and progress on emissions and waste reduction.